Antibiotic Dosing in Pediatric Intensive Care (ADIC)

Ghent University Hospital (UZ)

Status: Enrolling

Conditions: Vancomycin; Meropenem; Amikacin; Piperacillin-tazobactam; Ciprofloxacin; Amoxicillin-clavulanate; Teicoplanin; Pharmacokinetics

Treatments: Procedure: blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.; Procedure: blood sampling in patients receiving vancomycin as part of routine clinical care.; Procedure: blood sampling in patients receiving teicoplanin as part of routine clinical care.; Procedure: blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care; Procedure: blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.; Procedure: blood sampling in patients receiving amikacin as part of routine clinical care.; Procedure: blood sampling in patients receiving meropenem as part of routine clinical care.

Study type: Observational

Funder types: Other

Identifiers

NCT02456974

2012/172

Details and patient eligibility

About

Pharmacokinetics of antibiotics in critically ill neonates, infants and children

Enrollment: 640 estimated patients

Sex: All

Ages: 1 day to 16 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients admitted to the pediatric intensive care unit
• patient age/weight : 1,8 kg-15 years
• patient receiving antibiotic treatment (piperacillin-tazobactam, amoxicillin-clavulanate, vancomycin, teicoplanin, meropenem, ciprofloxacin, amikacin) via intermittent infusion regimen or continuous infusion according to institutional treatment guidelines
• intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)

Exclusion criteria

• no catheter in place for blood sampling
• absence of parental/patient consent
• known hypersensitivity to beta-lactam antibiotics, glycopeptides, fluoroquinolones, aminoglycosides
• extracorporeal circuit (haemodialysis, ECMO, peritoneal dialysis )

Trial design

640 participants in 7 patient groups

amoxicillin-clavulanate

Description:

Patients receiving amoxicillin-clavulanate as part of routine clinical care.

Treatment:

Procedure: blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care

piperacilline-tazobactam

Description:

Patients receiving piperacilline-tazobactam as part of routine clinical care.

Treatment:

Procedure: blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.

vancomycin

Description:

Patients receiving vancomycin as part of routine clinical care.

Treatment:

Procedure: blood sampling in patients receiving vancomycin as part of routine clinical care.

teicoplanin

Description:

Patients receiving teicoplanin as part of routine clinical care.

Treatment:

Procedure: blood sampling in patients receiving teicoplanin as part of routine clinical care.

meropenem

Description:

Patients receiving meropenem as part of routine clinical care.

Treatment:

Procedure: blood sampling in patients receiving meropenem as part of routine clinical care.

ciprofloxacin

Description:

Patients receiving ciprofloxacin as part of routine clinical care.

Treatment:

Procedure: blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.

amikacin

Description:

Patients receiving amikcain as part of routine clinical care.

Treatment:

Procedure: blood sampling in patients receiving amikacin as part of routine clinical care.